BioGaia has extended its collaboration with the Swiss pharmaceutical
company Ewopharma AG giving the company exclusive rights to sell
BioGaia's Probiotic Drops and Tablets, under the BioGaia trademark,
in Serbia and Croatia."We are very pleased to see the continued expansion in Central
Eastern Europe (CEE). The combination of Ewopharma's solid presence
in CEE and BioGaia's products based on strong scientific
documentation, has proven to be a success." says Peter Rothschild,
President, BioGaia AB. "We look forward to successful product
launches during 2009.""In light of the positive sales growth in our CEE countries, we are
eager to launch BioGaia drops and tablets in Serbia and Croatia" says
Martin Hongler, Vice President at Ewopharma. "The demand for
BioGaia's products is growing steadily in our markets and the
increasing scientific documentation in several indication areas
continue to impress".
Ewopharma AG is a privately held Swiss company of 50 years
experience, active on the pharmaceutical markets in Central Eastern
Europe. It has its headquarters in Schaffhausen (Switzerland) and
local subsidiaries in most CEE countries.
Latest press releases from BioGaia:
2009-03-04 BioGaia product launched as pharmaceutical in India
2009-03-02 BioGaia Probiotic chewable tablets effective in decreasing
diarrhoea caused by antibiotics
2009-02-12 Year-end report 2008
For additional information contact: Peter Rothschild, Managing
Director, telephone: +46 8 - 555 293 00,
Jan Annwall deputy Managing Director telephone: +46 8 - 555 293 00
BioGaia is a biotechnology company that develops, markets and sells
probiotic products with documented health benefits. The products are
primarily based on the lactic acid bacterium Lactobacillus reuteri
(Reuteri), which has probiotic, health-enhancing effects. The class B
share of the Parent Company BioGaia AB is quoted on the Small Cap
list of the Nordic Stock Exchange in Stockholm.
www.biogaia.com
